Pre-JAK2V617F era
Early studies showed that erythropoiesis in PV patients was hypersensitive to erythropoietin (Epo), 1, 2 and possibly independent of this cytokine. 3, 4 Culture of PV bone marrow cells produced colony forming unit-derived erythroid colonies in the absence of Epo, termed endogenous erythroid colonies (EEC), that were 9-37% of the erythroid colony number obtained in the presence of Epo. 3 Subsequently, growth of endogenous erythroid bursts from more primitive erythroid progenitors (burst forming unit-erythroid) was also demonstrated in PV patients. 5 Erythroid progenitors were also shown to be hypersensitive to other cytokines/growth factors, including interleukin (IL)-3, 6 insulin-like growth factor-1, 4 stem cell factor 7 and granulocytemacrophage colony stimulating factor. 8 Unlike in hereditary erythrocytosis where mutations in the Epo receptor (EpoR) cytoplasmic domain (or alternatively, in the von Hippel-Lindau (VHL) protein) may be evident (reviewed by Kralovics and Skoda 9 ), similar studies failed to identify EpoR mutations in patients with PV. 10, 11 Similarly, in early studies, endogenous megakaryocyte colony growth did not appear to be associated with mutations in c-mpl (MPL), the thrombopoietin receptor, in ET or PMF patients. 12 These data suggested that the molecular defect underlying cytokine hypersensitivity in MPD occurred downstream of the cytokine receptor. Several lines of evidence have indicated that a constitutive tyrosine kinase activity is important for PV pathogenesis. For instance, the mutant oncoproteins BCR-ABL and v-Src were capable of supporting normal erythroid development of fetal liver progenitor cells from EpoR(À/À) miceFthese data additionally that a unique tyrosine kinase activity may not be necessary for terminal erythroid differentiation. 13 Furthermore, several kinase inhibitors, including AG-490, a non-selective JAK inhibitor that is unsuitable for clinical development, have been shown to inhibit terminal erythroid differentiation in an Epo-free culture system that uses CD34 þ progenitor cells from PV patients. 14 Similarly, imatinib mesylate (Gleevec) has been shown to inhibit EEC growth in vitro, although its molecular target for this effect has not been identified. 15 A common link in the aforementioned data is JAK-2, which is the predominant tyrosine kinase of the JAK family of kinases (JAK1, JAK2, JAK3 and TYK2) that is activated in response to Epo, granulocyte-macrophage colony stimulating factor, IL-3, IL-5, thrombopoietin, growth hormone and prolactin-mediated signaling (reviewed by Ihle et al. 16 ). Indeed, the phenotype of JAK2-deficient mice is very similar (albeit more severe) to Epo-or EpoR-mutant mice, with embryonic lethality observed at day 12.5 due to absence of definitive erythropoiesis. 17, 18 In addition to mediating EpoR signaling via its kinase activity, JAK2 also enhances the normally inefficient folding of EpoR in the endoplasmic reticulum, thereby facilitating ligandindependent cell-surface expression of the latter. 19 Similarly, JAK2 (and TYK2) significantly enhances the cell-surface expression of MPL through stabilization of the mature form of the receptor. 20 Cumulatively, these data indicated that JAK2 kinase was an ideal candidate proto-oncogene in MPD.
JAK2V617F era
JAK2 was directly linked to MPD pathogenesis with the identification of JAK2V617F, a recurring gain-of-function mutation, in MPD patients. [21] [22] [23] [24] Involvement of JAK2 was consistent with earlier studies that identified loss of heterozygosity (LOH) in chromosome 9p (9pLOH) as the commonest chromosomal alteration in PV (B33% cases). 25 This cytogenetically occult change results from mitotic recombination (that is, acquired uniparental disomy), wherein homozygosity of all genes (and mutations) contained within the 9pLOH interval reflects a duplication event, rather than loss of the wild-type allele, as is seen with classical tumor suppressor genes (that is, hemizygosity). In this regard, PV patients exhibit homozygosity for the JAK2V617F allele more frequently than ET patients, in granulocytes 26 as well as in erythroid colonies. 27 While JAK2V617F is restricted to myeloid malignancies, it is not associated with a specific disease phenotypeFthe frequency of JAK2V617F using sensitive allele-specific assays is estimated to be 95% in PV, and 50% in ET and PMF. 26, 28 In contrast, p5% of patients with chronic myelomonocytic leukemia, myelodysplastic syndrome or de novo acute myeloid leukemia (AML) harbor this particular mutation. 29, 30 JAK2V617F has been identified in the hematopoietic stem cell compartment, 31 and has been demonstrated in non-myeloid cells including B and T lymphocytes, 32 as well as natural killer cells.
33 JAK2V617F recapitulates some of the key in vitro biological characteristics of MPDFfor instance, it increases the survival of cytokine-dependent cells cultured in the absence of cytokines, 21, 23, 24 and appears to promote ex vivo EEC growth from PV progenitor cells. 21 Furthermore, in vivo expression of JAK2V617F in a murine bone marrow transplant (BMT) assay produces an MPD phenotype resembling PV in these animals. [34] [35] [36] [37] The degree of JAK2V617F overexpression relative to endogenous wild-type JAK2 (JAK2WT) is relatively modest (2-to 3-fold) in this model. 36 Although the murine BMT model suggests that JAK2V617F may be sufficient for PV expression, it does not address other key issues, including the extent to which differences in JAK2V617F gene dosage determine which MPD is expressed (for example, PV or ET with higher or lower JAK2V617F levels, respectively). 26, 38 While JAK2V617F is the predominant disease-associated allele in MPD, it is becoming clear that other alleles may also be involved. In general, the novel allele, when present, is found in MPD cases that are JAK2V617F negative (for example, MPLW515L or MPLW515K), 39 although in rare cases, these alleles may occur in conjunction with JAK2V617F (for example, JAK2D620E, MPLW515L/K). [40] [41] [42] A similar co-occurrence of BCR-ABL and JAK2V617F alleles has also been described in MPD patientsFthe clinical phenotype in these patients (that is, chronic myeloid leukemia (CML) versus PV, for instance) may depend on which mutant clone is dominant. 43, 44 The MPLW515 mutations are restricted to patients with JAK2V617F-negative PMF (B10%) or JAK2V617F-negative ET (1%). More recently, a series of novel somatic mutations in JAK2 exon 12 were identified in rare cases of JAK2V617F-negative PV (representing B3% of all PV cases), particularly in those exhibiting a relatively isolated erythrocytosis, rather than the panmyelosis that typically characterizes PV. 45, 46 Other activating alleles of JAK kinases have also been described recently in acute megakaryoblastic leukemia cell lines, namely JAK2T875N 47 and JAK3A572V. 48 While these particular alleles have not been detected in patients as yet, they illustrate the potential for additional activating alleles involving JAK family members.
Pre-clinical studies JAK2V617F-activated signal transduction JAK2V617F appears to activate the same downstream signaling pathways as does JAK2WT in response to Epo stimulation, including STAT, extracellular signal-regulated kinase/mitogenactivated protein kinase and phosphatidylinositol 3 kinase/ protein kinase B (AKT) pathways, albeit in a cytokineindependent fashion. 21, 23, 24, 49 The particular importance of the STAT pathway is underscored by studies with ETS translocation variant 6 (ETV6)-TEL-Janus kinase 2 (JAK2), a fusion oncoprotein identified in human leukemiasFthis deregulated kinase leads to constitutive activation of STAT-5 in Ba/ F3 cells, and induces a lethal hematopoietic disease in mice in a BMT assay, a process that has been demonstrated to be STAT5a/b-dependent. [50] [51] [52] Under cytokine-free conditions, coexpression of JAK2WT reportedly competes with JAK2V617F in a dosedependent fashion, which is reflected in the suppression of JAK2V617F-mediated STAT-5 transcriptional activity in JAK2-deficient g-2A cells. 21 Although the molecular basis for this dominant-negative effect has not been elucidated (for example, competition for binding to EpoR or to downstream signaling molecules), it may explain the basis for selection of JAK2V617F-homozygous clones, since these are predicted to enjoy a selective growth advantage relative to JAK2V617F-heterozygous clones. Although JAK2V617F, MPLW515L and JAK2 exon 12 mutations appear to activate similar signaling pathways in vitro, their in vivo expression in murine BMT assays results in relatively distinct phenotypic featuresFfor instance, JAK2V617F is associated with predominant erythrocytosis (neutrophilia is seen only in the Balb/C background); in contrast, MPLW515L is associated with marked thrombocytosis (and increased bone marrow reticulin fibrosis). 21, [34] [35] [36] [37] 39 This contrasts with expression of most other activated tyrosine kinases (for example, BCR-ABL p210, TEL-JAK2, FLT3-ITD or FIP1L1-PDGFRA) in a similar assay, which results in a polyclonal MPD of short latency, that is characterized by a predominant overproduction of maturing neutrophils.
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JAK2 inhibitor development
At present, several groups are actively developing orally bioavailable, small-molecule inhibitors of JAK2 kinase. Broadly speaking, JAK2 inhibitors may be classified as 'JAK2-selective' (Class I) or 'non-JAK2 selective' (Class II) depending on whether or not the particular inhibitor was developed to primarily target JAK2 kinase (including JAK2V617F). Class II inhibitors were primarily developed for non-MPD indications but are still considered to have therapeutic potential in MPD given their significant 'off-target' JAK2 kinase-inhibitory activity. For Class I inhibitors, one strategy has been to refine an existing tyrphostin (tyrosine phosphorylation inhibitor) scaffold based on available molecular structural data for JAK2 and JAK3 kinase domains, 56, 57 to rationally design compounds that selectively bind to the JAK2 (relative to JAK3) kinase catalytic site at low nanomolar concentrations. 58, 59 Such a strategy yields compounds that are potent inhibitors of both wild-type (JAK2WT) and mutant (JAK2V617F) alleles. There are efforts underway, however, to develop cell-based screens that will identify allelespecific inhibitors of JAK2V617FFthese have the potential for a more optimal therapeutic window since only the disease allele will be inhibited.
Pre-clinical studies
There scant data if any in the public domain pertaining to the pre-clinical testing of JAK2 inhibitors, particularly for the Class I inhibitors that have recently entered clinical trials. Currently available data for JAK2 inhibitors are summarized in Table 1 .
Early studies on the effects of JAK2V617F inhibition made use of tool compounds (for example, AG-490, JAK inhibitor I) 65 that inhibit JAKs non-selectivelyFthese compounds, although sufficient for limited in vitro experiments that provide proof-ofprinciple, have no potential for further development as bona fide 'drugs' for the treatment of MPD.
In general, laboratory studies with JAK2 inhibitors have employed the following experimental systems: (i) cell lines known to harbor JAK2V617F (for example, human erythroleukemia cells) or that are engineered to express the mutant kinase (for example, Ba/F3-V617F); (ii) culture of hematopoietic progenitor cells from JAK2V617F-positive MPD patients; and (iii) in vivo studies using murine models of MPDFeither a xenograft model or JAK2V617F expression in a murine retroviral bone marrow transduction and transplantation assay.
The growth of cell lines harboring JAK2V617F or MPLW515L is inhibited at nanomolar concentrations by the JAK2-selective inhibitors TG101209 and TG101348. 58 The JAK2/JAK3 selectivity of these inhibitors has been assessed using leukemic cell lines that harbor either JAK2-or JAK3-activated allelesFCHRF (CHRF-288-11) cells (JAK2T875N) are observed to be more potently inhibited than CMK cells (JAK3A572V) in such experiments.
The effect on primary cells has been assessed by culturing progenitor cells in the presence of JAK2 inhibitors. In experiments with TG101209 and/or TG101348, we have observed the following: 58 (i) progenitors from MPD patients may be more sensitive to JAK2 inhibition than those from healthy controls, consistent with a greater dependence on JAK2 signaling in the former; (ii) EEC growth is inhibited at nanomolar concentrations, with preliminary data suggesting that some mutant alleles are more sensitive to inhibition than others (MPLW515L/KDJAK2 exon 12 mutation4JAK2V617F) (A Pardanani, unpublished observations). The corresponding Epo-supported erythroid colonies are less potently inhibited, reflecting the generally lower prevalence of JAK2 mutations in these colonies relative to EECs; (iii) EEC growth is also suppressed in patients who do not harbor a known MPD-associated mutation, indicating that the abnormal MPD clone in such cases is as dependent on deregulated JAK-STAT signaling as those with known JAK2 or MPL mutations; and (iv) in at least some cases, exposure to inhibitor results in the selective suppression of mutationharboring coloniesFin these cases, it is possible however that a fraction of the surviving colonies (JAK2WT) reflect persistence of a 'pre-JAK2' MPD clone that is less sensitive to JAK2 inhibition.
In a mouse xenograft model with Ba/F3-V617F cells, administration of TG101209 (200 mg day À1 ) by oral gavage rescued the animals from a fully penetrant, rapidly fatal hematopoietic malignancy. 58 A marked decrease in STAT-5 phosphorylation was evident in splenic tumors following administration of a single dose (100 mg kg À1 ) of TG101209, and in vivo therapeutic efficacy was correlated with a significant decrease in the circulating tumor burden in these animals. In an independent murine BMT model of PV, the continuous parenteral administration of AG-490 by subcutaneous infusion over a 2-week period resulted in a significant decrease in the hematocrit and reticulocyte count in recipients of JAK2V617F-(but not JAK2WT) transduced bone marrow. 36 Interestingly, a similar effect was seen with imatinib, but not with dasatinib (Sprycel), administered by oral gavage in this model, suggesting that Src kinase-directed therapies may not be efficacious for the treatment of PV. While the aforementioned studies are informative, they do not provide a detailed characterization of JAK2 inhibitor effects in mouse MPD models, particularly with regard to disease-relevant end points including blood counts, organomegaly, extramedullary hematopoiesis, bone marrow pathology and progenitor-cell function, although it is expected that such data will be forthcoming in the near future.
Clinical trials
Clinical trials with small-molecule JAK2 inhibitors that are ongoing or in development are summarized in Table 2 . All trials with Class I (JAK2-selective) inhibitors are first-in-human studiesFthe following issues are pertinent from the standpoint of clinical trials with this group of inhibitors:
Which of the MPD patient groups is most suited for initial (Phase I) studies with JAK2 inhibitors? Should eligibility be restricted to those patients who are JAK2V617F positive?
Until the toxicity profile including dose-limiting toxicities become apparent from ongoing Phase I studies, it is reasonable to restrict use of newer JAK2-selective inhibitors in the investigational setting to patients with 'high-risk' MPD. Such novel therapies are particularly appealing for patients with 'intermediate-risk' or 'high-risk' PMF (by standard criteria, for example, Mayo Clinic or Dupriez), 66, 67 given the significant disease-related morbidity in this setting (cachexia/other constitutional symptoms, hepatosplenomegaly, extramedullary hematopoiesis, symptomatic anemia, and so on) and the poor prognosis (median survival of 2-3 years) of these patients. 66, 67 At present, there is virtually no effective treatment for these patients, although recently introduced immunomodulatory drugs have shown promise 68 Fconventional therapies are palliative in intent (for example, prevention of thrombohemorrhagic complications), and do not alter the natural history of disease or prevent clonal evolution. Furthermore, only a minority of patients are eligible for potentially curative allogeneic stem cell transplants after either fully myeloablative 69, 70 or reduced-intensity conditioning. 71, 72 In contrast to patients with PMF, those with ET or PV have a considerably longer life expectancy (median survival exceeds 20 years with conventional therapy, with some combination of phlebotomy7low-dose aspirin7hydroxyurea). 73, 74 Consequently, it is difficult at present to justify the initial use of JAK2 inhibitors in unselected ET or PV patients until the safety and tolerability of these agents at therapeutically active doses has been confirmed in higher risk MPD patients. It may be possible, however, to identify PV or ET patients at high risk for myelofibrotic and/or leukemic transformation as potential candidates for up-front JAK2 inhibitor therapy. 75 Up to 50% of ET and PMF patients and 5% of PV patients are JAK2V617F negativeFalternative mutant alleles (some yet to be identified) constitutively activate JAK2 signaling to account for the myeloproliferation observed in these patients. Limited in vitro data suggest that JAK2-selective inhibitors suppress hematopoietic colony growth even in the absence of JAK2V617FFin such assays, progenitors harboring MPLW515L/K mutations (or no identifiable mutation) appear to be inhibited at least as potently as those harboring JAK2V617F. 58 These observations raise the possibility that most, if not all, MPD patients in 'chronic phase' may ultimately qualify for JAK2 inhibitor-based therapy, at least from the standpoint of disease mechanism. In the case of leukemic transformation of MPD however, the leukemic blasts in most instances are found to be JAK2V617 negative, which indicates that both the MPD clone and the subsequently evolved AML clone (that are positive and negative for JAK2V617F, respectively) are derived from a common ancestral 'pre-JAK2' clone. 76, 77 Consequently, it appears unlikely at the present time that JAK2 inhibitors will have a central role in treating JAK2V617F-negative AML that evolves from pre-existing JAK2V617F-positive MPD, although it should be pointed out that STAT-3 and STAT-5a/b activation in leukemic blasts has been described previously. 78 How should treatment responses be assessed in these studies? Which correlative studies are likely to be the most useful in this regard?
Treatment responses are assessed using a combination of (i) disease-specific clinical measures and (ii) biological surrogates that reflect inhibition of disease-related molecular signaling (that is constitutive JAK2 kinase activity) and/or suppression of the abnormal hematopoietic clone. In the case of PMF, the recently proposed International Working Group consensus criteria capture traditional measures of response for this diseaseFclinical (that is, resolution of disease-related symptoms and signs, including hepatosplenomegaly), hematologic (that is, normalization of peripheral blood counts, and resolution of leukoerythroblastosis) and histologic (that is, resolution of osteomyelofibrosis). 79 Although not incorporated into the formal response criteria, the International Working Group document emphasizes the importance of collecting information on cytogenetic and/or molecular markers in PMF patients, if available, both at baseline and during follow-up. This supplementary information is likely to become increasingly important in the near future as the various biologic markers are validated in a prospective fashion to track clinically meaningful responses.
Given the availability of reliable quantitative assays, monitoring of JAK2V617F mutation burden is feasible, and will be an important element of JAK2 inhibitor trials, to assess the depth of response, as well as the extent to which suppression of the mutant clone correlates with clinical responses. Such assays have already been used to assess the molecular response to treatment of PV to interferon [80] [81] [82] or after allogeneic stem cell transplantation. 83 A similar response has been observed with lenalidomide (Revlimid) therapy in a patient who concurrently harbored the del(5)(q31) cytogenetic abnormality. 84 In patients without identifiable cytogenetic or molecular abnormalities, other assays such as EEC growth or X-chromo- some inactivation pattern analysis in informative females, which are although more cumbersome and less reliable than JAK2V617F monitoring, may provide additional information regarding treatment-related effects on the abnormal MPD clone.
Inhibition of JAK2 (and JAK2V617F) kinase-induced tyrosine phosphorylation can also be monitored in biological specimens collected during the course of clinical trials with JAK2 inhibitors, although such assays are more cumbersome than monitoring of JAK2V617F allele burden. In this regard, it may be feasible to follow substrates of JAK2 kinase, akin to the monitoring of CRKL phosphorylation as a surrogate for BCR-ABL kinase activity in neutrophils of CML patients undergoing treatment with imatinib. 85 The degree to which STAT-5 and/or STAT-3 phosphorylation is inhibited in peripheral blood cells that are stimulated ex vivo with an appropriate cytokine (for example, IL-6, granulocyte-macrophage colony stimulating factor) can be quantitatively monitored by phospho-flow analysis in patients treated with JAK2 inhibitors in ongoing clinical trials.
What are the predicted class-specific toxicities of JAK2-selective inhibitors? What are the likely consequences of JAK3 inhibition?y. of wild-type JAK2 inhibition? What have we learned from studies with non-JAK2 selective inhibitors?
Detailed information regarding inhibitor effects either from animal toxicology studies or from use in human subjects is presently unavailable because such information is proprietary and/or preliminary. Until such information becomes publically available, concerns relating to the safety of JAK2-selective inhibitors in MPD patients will persist. In considering potential class-specific toxicities, these concerns relate primarily to potential untoward effects resulting from inhibition of (i) wildtype JAK2 and/or (ii) JAK3.
The JAK family members mediate signaling from enzymatically deficient type I/II cytokine receptors, which bind over 50 different cytokines that regulate a broad range of physiologic processes in mammals ranging from body growth to adiposity, and include hematopoiesis and innate/adaptive immune responses (reviewed by O'Shea et al.
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). The cytokines are subdivided based on their selective use of shared receptor subunits, including the common gamma chain (gc) subunit (includes IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21) and gp130 subunit (includes IL-6, IL-11, oncostatin M, G-CSF and so on). Within cells, the JAKs associate with specific cytokine receptors (for example, JAK3 with gc, and JAK1 with gc or gp130 receptor subfamilies, respectively) once cytokines have bound to their cognate receptors. While JAK1, JAK2 and TYK2 are ubiquitously expressed, the expression of JAK3 appears to be restricted to hematopoietic cells. The generation of knockout mice has helped elucidate JAK functionsFJAK1-deficient mice are viable but die in the early post-natal period due to failure to nurse; 87 JAK2 deficiency is embryonically lethal due to failure of definitive hematopoiesis; 17, 18 JAK3-deficient mice are viable and fertile but display a severe combined immunodeficiency phenotype. 88 Indeed, there were concerns during the early development of imatinib mesylate (Gleevec) for the treatment of CML that 'offtarget' inhibition of non-BCR-ABL tyrosine kinases (c-ABL, PDGFR, KIT, ARG) may lead to undue toxicity 89 Fin this regard, it was known for instance that c-abl knockout mice exhibit decreased neonatal viability as well as lymphopenia. 90 Clinical experience with imatinib however reveals it to be a remarkably safe agentFin their latest update of IRIS study patients, Druker et al. 91 report that after a median follow-up of 60 months, only 4% of patients initially assigned to the imatinib treatment arm discontinued treatment due to an adverse event. These data suggest that significant mutant-over-wild-type selectivity may not be essential for therapeutic efficacy of small-molecule tyrosine kinase inhibitors. Recent in vitro studies with the JAK2-selective inhibitor TG101209 indicates a modest 'therapeutic window', wherein progenitor cells from JAK2V617F-positive MPD patients are observed to be more sensitive to TG101209's inhibitory effects than progenitors from healthy controls.
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MK-0457 (formerly, VX-680) is a small-molecule inhibitor of the Aurora kinases (AUR A, B and C) 92 that is also active (nanomolar potency) against a small set of wild-type and mutant tyrosine kinases, including BCR-ABL/ABL, 93 JAK2 60 and FLT3. MK-0457 is currently being studied in patients with CML or Ph þ acute lymphocytic leukemia who harbor the T315I mutation (Phase II), as well as in patients with relapsed/ refractory leukemias, including those with refractory or transformed JAK2V617F-positive MPD (Phase I). 60, 94, 95 Although dose-dependent myelosuppression was seen at all dose levels studied (8-32 mg m À2 h À1 administered by a continuous 5-day intravenous infusion), no extramedullary XGrade 3 adverse events attributable to MK-0457 were noted in preliminary reports from these studies.
CEP-701 (Lestaurtinib) is a small-molecule inhibitor of TRKA that was originally developed for possible use in prostate cancer. It was subsequently recognized to have FLT3-inhibitory activity (nanomolar potency), 96 and was consequently evaluated in a Phase I/II study in heavily pre-treated patients with refractory/ relapsed or poor-risk AML who harbored FLT3-activating mutations. 97 In both this study and a subsequent Phase II study in older AML patients, 98 CEP-701 was relatively well tolerated (commonest reported adverse event was mild GI intolerance); however, only modest clinical efficacy was observed in these patients. More recently, CEP-701 has been reported to inhibit JAK2 kinase (IC 50 ¼ 1 nM in kinase assays) and also inhibit the proliferation of progenitor cells from MPD patients in vitro. 61 An ongoing Phase II study is examining the efficacy of CEP-701 in PMF patients.
CP-690,550 is an orally bioavailable JAK3 inhibitor with nanomolar potency that is currently in clinical trials in renal transplant patients for prevention of acute rejection and in rheumatoid arthritis as a novel immunosuppressive agent. It was shown previously to prolong survival in animal models of heart and kidney allotransplantation. 99 In animal studies, dosedependent anemia was commonly seen, which is consistent with its known 'off-target' JAK2-inhibitory activity (20-fold less JAK2 inhibition as compared to JAK3) 99 Finterestingly, it was possible to overcome the suppressive effect on erythropoiesis by administering exogenous Epo in cynomolgus monkeys that were exposed to lower levels of the drug. 100 Chronic exposure to CP-690,550 has been reported to cause changes in immune cell subsets in rodent 101 and monkey allotransplant models, 102 an effect that is reflected primarily in reduced numbers of natural killer cells and CD8 þ T lymphocytes; in contrast, B-lymphocyte numbers may be relatively preserved. Data from the aforementioned studies suggest that dosedependent cytopenias may be commonly observed, and could represent the dose-limiting toxicity in Phase I studies with JAK2-selective inhibitors. Such a finding would not be surprising given the known importance of JAK2WT signaling in normal hematopoiesis. It may turn out however, as underscored by the experience with imatinib in CML, that significant mutantover-wild-type selectivity may not be necessary for therapeutic efficacy with this class of kinase inhibitors. Moreover, the Class I JAK2 inhibitor therapy in MPD A Pardanani (JAK2-selective) inhibitors are X100-fold more selective for JAK2 relative to JAK3Fthis ought to, in theory, limit the potential immunosuppressive effects of these inhibitors, as compared to Class II inhibitors such as MK-0457. Whether this particular characteristic of JAK2-selective inhibitors will translate into a more favorable safety profile, however, remains to be demonstrated in clinical studies. In this regard, it will be informative to monitor both qualitative and quantitative aspects of immune function, at baseline and during follow-up, in MPD patients who are treated with JAK2 inhibitors in ongoing clinical trials.
